ASCO® 2023

Presentations

SGN-BB228 | Solid Tumors | Abstract #TPS9597

Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001: trial in progress)